As insulin sensitizers, they may modify CV risk factors and reduce CV mortality in T2DM and insulin resistance subjects.[16] The ACE inhibitors therapy reduces both microvascular and macrovascular complications in diabetes and appears to improve insulin sensitivity and glucose metabolism.[17] This review focuses on the potential roles of rosiglitazone, a member of TZD class of antidiabetic agents, and ramipril, an ACE inhibitor, in preventing the preclinical macrovasculopathy in diabetes and IGT population. This evidence concerns the gene ACE and diabetes mellitus.